BioCryst To Start Pivotal BCX9930 Trial In Rare Blood Disorder In 2H'21

BioCryst Pharmaceuticals Inc BCRX announced results from a dose-ranging trial evaluating BCX9930 in treatment-naïve paroxysmal nocturnal hemoglobinuria (PNH) patients and PNH patients with an inadequate response to C5 inhibitors.

  • The results showed that BCX9930 significantly increased hemoglobin and reduced transfusions, was safe and generally well-tolerated in the trial.
  • Based on these results, the company plans to advance directly into pivotal trials in PNH and proof of concept trials in renal complement-mediated diseases in the second half of 2021.
  • PNH patients in the trial also experienced reductions in key laboratory biomarkers such as reticulocyte count, lactate dehydrogenase (treatment-naïve patients), and percentage of C3 opsonization (patients with inadequate C5 response) following dosing at 400 mg bid or 500 mg bid.
  • Hemoglobin levels increased by a mean of 3.5 g/dL in treatment-naïve patients and 3.2 g/dL in C5 inhibitor inadequate response patients; at the last visit, mean hemoglobin levels were 11.8 g/dL and 12.2 g/dL, respectively.
  • Relative red blood cell clone size, a marker of hemolytic control, also increased from 53% to 92% in treatment-naïve patients and from 50% to 80% in C5 inhibitor inadequate response patients.
  • There were no discontinuations or drug interruptions due to related adverse events. No safety signals were observed.
  • Price Action: BCRX shares are trading 2.04% higher at $13.51 in premarket trading on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareFDAGeneralParoxysmal Nocturnal Hemoglobinuria
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!